Magnetic Ventures

Terrain BioSciences is in the field of RNA-based therapeutics and vaccine development. Leveraging advanced AI and proprietary manufacturing platforms, Terrain BioSciences addresses the challenges of designing, selecting, manufacturing, and delivering optimal RNA sequences. Terrain BioSciences collaborates with over a dozen biotech firms to enhance the expression, durability, and manufacturability of RNA sequences, significantly accelerating their path to clinical application. With a focus on personalized cancer vaccines and other RNA-based modalities, Terrain BioSciences is at the forefront of the next generation of programmable medicines.

Weave is a biomedicine-focused company based in the United States that offers an artificial intelligence collaboration platform. This platform specializes in generating regulatory submissions, including Investigational New Drug applications. By automating clinical note abstraction pipelines and linking multimodal datasets, Weave enhances the efficiency of research and development processes. The platform facilitates collaboration among regulatory, research, and clinical teams, allowing them to organize, edit, and summarize source materials into submission-ready documents within a day. This capability accelerates the discovery of various data modalities, empowering researchers to make faster and more informed decisions in drug development.

Relation Therapeutics is a biotechnology company focused on advancing drug discovery and development. It utilizes human genetics and clinical omics data, alongside patient-derived tissue samples, to identify and validate therapeutic programs. The company employs machine learning to explore the relationships between genes, proteins, and drugs, generating insights that have real translational validity. By combining single-cell multi-omics from patient tissues with functional assays, Relation Therapeutics aims to deepen the understanding of biological processes in human health and disease. This approach enables healthcare providers to discover and develop novel treatments, particularly in areas with unmet medical needs.

Paradigm is rebuilding the clinical research ecosystem by developing a platform that allows all patients equitable access to trials while improving trial efficiency and lowering barriers to participation for healthcare providers. It is an innovative company that is dedicated to transforming the clinical research ecosystem. Their mission is to create a more accessible and equitable healthcare system by developing a platform that enables patients from diverse backgrounds to participate in clinical trials. Clinical trials are essential for testing and developing new drugs, therapies, and medical devices, but historically, they have been plagued by inefficiencies, barriers to access, and inequities in patient representation. Paradigm aims to solve these challenges by creating a platform that uses technology and data-driven insights to streamline the clinical trial process, making it more efficient, cost-effective, and inclusive. The Paradigm platform is designed to facilitate seamless communication and collaboration among all stakeholders involved in clinical research, including patients, healthcare providers, pharmaceutical companies, and regulatory agencies. By leveraging technology such as AI, machine learning, and predictive analytics, Paradigm can identify and match eligible patients to clinical trials, streamline the recruitment and enrollment process, and provide real-time data insights to all stakeholders. Overall, Paradigm's innovative approach to clinical research has the potential to revolutionize the healthcare industry by improving patient outcomes, reducing healthcare costs, and accelerating the development of new treatments and therapies.

Project Eaden develops and licenses technologies for producing sustainable food and plant-based meat alternatives. Its platform creates products that mimic the taste, texture, and nutrition of animal meat, aiming to reduce greenhouse gas emissions, water usage, and land use associated with traditional meat consumption.

Relation Therapeutics is a biotechnology company focused on advancing drug discovery and development. It utilizes human genetics and clinical omics data, alongside patient-derived tissue samples, to identify and validate therapeutic programs. The company employs machine learning to explore the relationships between genes, proteins, and drugs, generating insights that have real translational validity. By combining single-cell multi-omics from patient tissues with functional assays, Relation Therapeutics aims to deepen the understanding of biological processes in human health and disease. This approach enables healthcare providers to discover and develop novel treatments, particularly in areas with unmet medical needs.

Transition Bio, Inc. is a biotechnology company dedicated to advancing human health through the discovery, analysis, and modulation of biological condensates. Founded in 2020 and based in Cambridge, Massachusetts, with a branch in Cambridge, United Kingdom, the company has developed a hypothesis-free drug discovery and diagnostics platform known as Condensomics. This innovative platform leverages droplet microfluidic technologies and protein biophysics to study condensates with remarkable precision, providing medical practitioners with detailed molecular mappings. Transition Bio's approach is designed to unlock new opportunities for drug development, setting it apart in the biopharmaceutical landscape.

Founded in 2017, Spotlight Therapeutics develops innovative therapeutics based on its targeted active gene editing platform. The company focuses on creating biologics tailored to specific cell populations, with initial programs in immuno-oncology, ophthalmology, and hematology.

National Resilience, also known as Resilience, is a biopharmaceutical manufacturing and technology company that provides end-to-end manufacturing and development solutions for diverse modalities, including cell and gene therapies, viral vectors, vaccines, and proteins. It actively invests in developing new manufacturing technologies to expand access to complex medicines and supports partners through the full lifecycle from development to commercial supply. The company was incorporated in 2020 and is based in La Jolla, California.

Deep Genomics is a Toronto-based company founded in 2014. It specializes in developing individualized genetic medicines using artificial intelligence systems to accelerate drug discovery and development processes, including target discovery, lead optimization, toxicity assessment, and innovative trial design. The company focuses on therapies for rare metabolic, ophthalmologic, and neurodegenerative disorders, utilizing oligonucleotide therapies that target genetic determinants of disease at the RNA or DNA level.

Founded in 2019, HiberCell is a biotechnology company based in New York. It develops therapeutics focused on preventing cancer relapse and metastasis by targeting adaptive stress pathways and immune modulation.

AppliedVR is a Los Angeles‑based company that develops virtual reality therapeutic devices for pain and anxiety management in healthcare settings. Founded in 2013, it partners with institutions such as Cedars‑Sinai and Children’s Hospital Los Angeles to deliver its VR platform in hospitals, surgery centers, and exam rooms across the United States. The company’s flagship product, EaseVRx, is the first VR‑based prescription therapeutic to receive FDA Breakthrough Device Designation; it combines cognitive behavioral therapy and mindfulness to help patients alter pain perception and build coping skills. EaseVRx is self‑administered at home, enabling remote care and improving access, equity, and efficiency in chronic pain treatment. AppliedVR’s clinically validated, on‑demand platform supports both acute and chronic pain, promotes non‑drug pain management, and assists clinicians in achieving better long‑term patient outcomes.

SameSky Health specializes in multicultural patient engagement solutions. Its platform connects payers, providers, and health systems with diverse Medicare populations, offering multi-channel messaging, care navigation, data insights, and consultancy services to enhance engagement, reduce emergency room visits, and improve healthcare outcomes.

National Resilience, also known as Resilience, is a biopharmaceutical manufacturing and technology company that provides end-to-end manufacturing and development solutions for diverse modalities, including cell and gene therapies, viral vectors, vaccines, and proteins. It actively invests in developing new manufacturing technologies to expand access to complex medicines and supports partners through the full lifecycle from development to commercial supply. The company was incorporated in 2020 and is based in La Jolla, California.

National Resilience, also known as Resilience, is a biopharmaceutical manufacturing and technology company that provides end-to-end manufacturing and development solutions for diverse modalities, including cell and gene therapies, viral vectors, vaccines, and proteins. It actively invests in developing new manufacturing technologies to expand access to complex medicines and supports partners through the full lifecycle from development to commercial supply. The company was incorporated in 2020 and is based in La Jolla, California.

Emme, Inc. is a healthcare technology company based in San Francisco, California, focused on improving women's health, particularly in the area of birth control. The company has developed an integrated smart case device and mobile application designed to help women take their birth control pills consistently. This multi-sensor technology tracks pill consumption, alleviates the need for users to remember to take their medication, and alerts those at risk of unintended pregnancy when back-up contraception is necessary. Additionally, the accompanying app provides users with a comprehensive overview of their health by enabling tracking of menstrual cycles, moods, and side effects. Emme aims to modernize the birth control experience, making it more user-friendly and aligned with the demands of contemporary life.

Amagma Therapeutics is a biotechnology company founded in 2019 and based in Waltham, Massachusetts. The company focuses on the discovery and development of antibody therapeutics aimed at addressing inflammatory diseases caused by enzyme hyperactivity. Specifically, Amagma's therapies target overactive extracellular proteases, which lead to tissue damage and contribute to widespread inflammatory responses. By developing these innovative treatments, Amagma aims to enhance therapeutic efficacy while ensuring patient safety in the management of human diseases linked to enzyme dysfunction.

Deep Genomics is a Toronto-based company founded in 2014. It specializes in developing individualized genetic medicines using artificial intelligence systems to accelerate drug discovery and development processes, including target discovery, lead optimization, toxicity assessment, and innovative trial design. The company focuses on therapies for rare metabolic, ophthalmologic, and neurodegenerative disorders, utilizing oligonucleotide therapies that target genetic determinants of disease at the RNA or DNA level.

Founded in 2019, HiberCell is a biotechnology company based in New York. It develops therapeutics focused on preventing cancer relapse and metastasis by targeting adaptive stress pathways and immune modulation.